HRP20100651T1 - 5,7-DIAMINOPIRAZOLO[4,3-d]PIRIMIDINI S AKTIVNOSCU INHIBITORA PDE-5 - Google Patents
5,7-DIAMINOPIRAZOLO[4,3-d]PIRIMIDINI S AKTIVNOSCU INHIBITORA PDE-5 Download PDFInfo
- Publication number
- HRP20100651T1 HRP20100651T1 HR20100651T HRP20100651T HRP20100651T1 HR P20100651 T1 HRP20100651 T1 HR P20100651T1 HR 20100651 T HR20100651 T HR 20100651T HR P20100651 T HRP20100651 T HR P20100651T HR P20100651 T1 HRP20100651 T1 HR P20100651T1
- Authority
- HR
- Croatia
- Prior art keywords
- ring
- compound according
- nitrogen
- alkyl
- optionally substituted
- Prior art date
Links
- ZTAWTRPFJHKMRU-UHFFFAOYSA-N 7-deaza-8-aza-2,6-diaminopurine Chemical class NC1=NC(N)=C2NN=CC2=N1 ZTAWTRPFJHKMRU-UHFFFAOYSA-N 0.000 title 1
- 101100296726 Caenorhabditis elegans pde-5 gene Proteins 0.000 title 1
- 230000002401 inhibitory effect Effects 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims abstract 89
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims abstract 68
- 229910052757 nitrogen Inorganic materials 0.000 claims abstract 43
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims abstract 40
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims abstract 40
- 229910052760 oxygen Inorganic materials 0.000 claims abstract 40
- 239000001301 oxygen Chemical group 0.000 claims abstract 40
- 125000005842 heteroatom Chemical group 0.000 claims abstract 37
- 239000011593 sulfur Chemical group 0.000 claims abstract 33
- 229910052717 sulfur Chemical group 0.000 claims abstract 33
- 125000004429 atom Chemical group 0.000 claims abstract 28
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract 27
- 239000001257 hydrogen Substances 0.000 claims abstract 27
- -1 5-trifluoromethyl-1,2,4-triazol-3-yl Chemical group 0.000 claims abstract 26
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims abstract 22
- 125000002950 monocyclic group Chemical group 0.000 claims abstract 21
- 125000001072 heteroaryl group Chemical group 0.000 claims abstract 20
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims abstract 19
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims abstract 19
- 229910052736 halogen Inorganic materials 0.000 claims abstract 15
- 125000000753 cycloalkyl group Chemical group 0.000 claims abstract 14
- 150000002367 halogens Chemical class 0.000 claims abstract 12
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims abstract 12
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims abstract 11
- 150000002431 hydrogen Chemical class 0.000 claims abstract 10
- 125000005347 halocycloalkyl group Chemical group 0.000 claims abstract 6
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims abstract 6
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims abstract 5
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims abstract 5
- 125000003367 polycyclic group Chemical group 0.000 claims abstract 5
- 125000004737 (C1-C6) haloalkoxy group Chemical group 0.000 claims abstract 4
- 125000003118 aryl group Chemical group 0.000 claims abstract 4
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims abstract 3
- 125000006376 (C3-C10) cycloalkyl group Chemical group 0.000 claims abstract 3
- 125000005036 alkoxyphenyl group Chemical group 0.000 claims abstract 3
- 125000000217 alkyl group Chemical group 0.000 claims abstract 3
- 125000004043 oxo group Chemical group O=* 0.000 claims abstract 3
- 125000004299 tetrazol-5-yl group Chemical group [H]N1N=NC(*)=N1 0.000 claims abstract 3
- 125000006717 (C3-C10) cycloalkenyl group Chemical group 0.000 claims abstract 2
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims abstract 2
- 125000004648 C2-C8 alkenyl group Chemical group 0.000 claims abstract 2
- 150000001732 carboxylic acid derivatives Chemical class 0.000 claims abstract 2
- 125000001624 naphthyl group Chemical group 0.000 claims abstract 2
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 10
- 125000006413 ring segment Chemical group 0.000 claims 10
- 150000003839 salts Chemical class 0.000 claims 8
- 239000012453 solvate Substances 0.000 claims 8
- 239000005864 Sulphur Substances 0.000 claims 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 7
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 7
- 125000004122 cyclic group Chemical group 0.000 claims 6
- 239000003814 drug Substances 0.000 claims 6
- 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 claims 5
- 201000010099 disease Diseases 0.000 claims 5
- 125000003386 piperidinyl group Chemical group 0.000 claims 5
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims 5
- 229920006395 saturated elastomer Polymers 0.000 claims 5
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 4
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 4
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 4
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 4
- 125000003226 pyrazolyl group Chemical group 0.000 claims 4
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims 3
- 206010007559 Cardiac failure congestive Diseases 0.000 claims 3
- 206010019280 Heart failures Diseases 0.000 claims 3
- 125000002393 azetidinyl group Chemical group 0.000 claims 3
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 3
- 125000000392 cycloalkenyl group Chemical group 0.000 claims 3
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 claims 3
- 125000004458 methylaminocarbonyl group Chemical group [H]N(C(*)=O)C([H])([H])[H] 0.000 claims 3
- 125000002757 morpholinyl group Chemical group 0.000 claims 3
- 239000000825 pharmaceutical preparation Substances 0.000 claims 3
- 125000004076 pyridyl group Chemical group 0.000 claims 3
- 208000011580 syndromic disease Diseases 0.000 claims 3
- 125000001412 tetrahydropyranyl group Chemical group 0.000 claims 3
- ZUHZNKJIJDAJFD-UHFFFAOYSA-N 1-(2-ethoxyethyl)-5-[ethyl(methyl)amino]-7-[(4-methylpyridin-2-yl)amino]-n-methylsulfonylpyrazolo[4,3-d]pyrimidine-3-carboxamide Chemical compound C=12N(CCOCC)N=C(C(=O)NS(C)(=O)=O)C2=NC(N(C)CC)=NC=1NC1=CC(C)=CC=N1 ZUHZNKJIJDAJFD-UHFFFAOYSA-N 0.000 claims 2
- PTRFPGZJULTQHY-UHFFFAOYSA-N 1-(2-ethoxyethyl)-5-[methyl(propan-2-yl)amino]-7-[(4-methylpyridin-2-yl)amino]-n-methylsulfonylpyrazolo[4,3-d]pyrimidine-3-carboxamide Chemical compound C=12N(CCOCC)N=C(C(=O)NS(C)(=O)=O)C2=NC(N(C)C(C)C)=NC=1NC1=CC(C)=CC=N1 PTRFPGZJULTQHY-UHFFFAOYSA-N 0.000 claims 2
- OLYAXYOJQGRXCA-UHFFFAOYSA-N 1-(2-ethoxyethyl)-5-[methyl(propan-2-yl)amino]-7-[(4-methylpyridin-2-yl)amino]pyrazolo[4,3-d]pyrimidine-3-carboxylic acid Chemical compound C=12N(CCOCC)N=C(C(O)=O)C2=NC(N(C)C(C)C)=NC=1NC1=CC(C)=CC=N1 OLYAXYOJQGRXCA-UHFFFAOYSA-N 0.000 claims 2
- HXOCQKOPTWWGOM-UHFFFAOYSA-N 1-(2-ethoxyethyl)-5-[methyl(propyl)amino]-7-[(4-methylpyridin-2-yl)amino]pyrazolo[4,3-d]pyrimidine-3-carboxylic acid Chemical compound C=12N(CCOCC)N=C(C(O)=O)C2=NC(N(C)CCC)=NC=1NC1=CC(C)=CC=N1 HXOCQKOPTWWGOM-UHFFFAOYSA-N 0.000 claims 2
- FXAPHZLIRCXSHM-UHFFFAOYSA-N 1-(2-ethoxyethyl)-7-(4-fluoro-3-methylanilino)-5-[methyl(propan-2-yl)amino]pyrazolo[4,3-d]pyrimidine-3-carboxylic acid Chemical compound C=12N(CCOCC)N=C(C(O)=O)C2=NC(N(C)C(C)C)=NC=1NC1=CC=C(F)C(C)=C1 FXAPHZLIRCXSHM-UHFFFAOYSA-N 0.000 claims 2
- UUUHXMGGBIUAPW-UHFFFAOYSA-N 1-[1-[2-[[5-amino-2-[[1-[5-(diaminomethylideneamino)-2-[[1-[3-(1h-indol-3-yl)-2-[(5-oxopyrrolidine-2-carbonyl)amino]propanoyl]pyrrolidine-2-carbonyl]amino]pentanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbon Chemical compound C1CCC(C(=O)N2C(CCC2)C(O)=O)N1C(=O)C(C(C)CC)NC(=O)C(CCC(N)=O)NC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C1CCCN1C(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C1CCC(=O)N1 UUUHXMGGBIUAPW-UHFFFAOYSA-N 0.000 claims 2
- DNUMLNJTFKGLMZ-UHFFFAOYSA-N 3-[1-(2-ethoxyethyl)-5-[ethyl(methyl)amino]-7-[(4-methylpyridin-2-yl)amino]pyrazolo[4,3-d]pyrimidin-3-yl]-2h-1,2,4-oxadiazol-5-one Chemical compound C12=NC(N(C)CC)=NC(NC=3N=CC=C(C)C=3)=C2N(CCOCC)N=C1C1=NC(=O)ON1 DNUMLNJTFKGLMZ-UHFFFAOYSA-N 0.000 claims 2
- 201000004384 Alopecia Diseases 0.000 claims 2
- 208000024827 Alzheimer disease Diseases 0.000 claims 2
- 206010002153 Anal fissure Diseases 0.000 claims 2
- 206010002383 Angina Pectoris Diseases 0.000 claims 2
- 102100030988 Angiotensin-converting enzyme Human genes 0.000 claims 2
- 208000016583 Anus disease Diseases 0.000 claims 2
- 201000001320 Atherosclerosis Diseases 0.000 claims 2
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 claims 2
- 206010005053 Bladder neck obstruction Diseases 0.000 claims 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 2
- 208000032544 Cicatrix Diseases 0.000 claims 2
- 208000005872 Diffuse Esophageal Spasm Diseases 0.000 claims 2
- 208000005171 Dysmenorrhea Diseases 0.000 claims 2
- 206010013935 Dysmenorrhoea Diseases 0.000 claims 2
- 206010016654 Fibrosis Diseases 0.000 claims 2
- 208000009531 Fissure in Ano Diseases 0.000 claims 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims 2
- 206010020772 Hypertension Diseases 0.000 claims 2
- 206010021639 Incontinence Diseases 0.000 claims 2
- 208000001145 Metabolic Syndrome Diseases 0.000 claims 2
- 206010027476 Metastases Diseases 0.000 claims 2
- 229910002651 NO3 Inorganic materials 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 claims 2
- 208000008589 Obesity Diseases 0.000 claims 2
- 208000002193 Pain Diseases 0.000 claims 2
- 108090000882 Peptidyl-Dipeptidase A Proteins 0.000 claims 2
- 208000005107 Premature Birth Diseases 0.000 claims 2
- 206010036590 Premature baby Diseases 0.000 claims 2
- 208000004403 Prostatic Hyperplasia Diseases 0.000 claims 2
- 201000004681 Psoriasis Diseases 0.000 claims 2
- 206010039085 Rhinitis allergic Diseases 0.000 claims 2
- 201000001880 Sexual dysfunction Diseases 0.000 claims 2
- 206010040893 Skin necrosis Diseases 0.000 claims 2
- 208000003800 Urinary Bladder Neck Obstruction Diseases 0.000 claims 2
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims 2
- 206010001053 acute respiratory failure Diseases 0.000 claims 2
- 125000005466 alkylenyl group Chemical group 0.000 claims 2
- 201000009961 allergic asthma Diseases 0.000 claims 2
- 201000010105 allergic rhinitis Diseases 0.000 claims 2
- 208000006673 asthma Diseases 0.000 claims 2
- 210000004204 blood vessel Anatomy 0.000 claims 2
- 206010006451 bronchitis Diseases 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 208000023819 chronic asthma Diseases 0.000 claims 2
- 208000029078 coronary artery disease Diseases 0.000 claims 2
- 206010012601 diabetes mellitus Diseases 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- 230000004761 fibrosis Effects 0.000 claims 2
- 239000008103 glucose Substances 0.000 claims 2
- 230000003676 hair loss Effects 0.000 claims 2
- 208000014617 hemorrhoid Diseases 0.000 claims 2
- 125000002883 imidazolyl group Chemical group 0.000 claims 2
- 230000008991 intestinal motility Effects 0.000 claims 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 2
- 125000000842 isoxazolyl group Chemical group 0.000 claims 2
- 201000006417 multiple sclerosis Diseases 0.000 claims 2
- 150000002823 nitrates Chemical class 0.000 claims 2
- 235000020824 obesity Nutrition 0.000 claims 2
- 125000001715 oxadiazolyl group Chemical group 0.000 claims 2
- 125000002971 oxazolyl group Chemical group 0.000 claims 2
- 230000036407 pain Effects 0.000 claims 2
- 210000005259 peripheral blood Anatomy 0.000 claims 2
- 239000011886 peripheral blood Substances 0.000 claims 2
- 201000010065 polycystic ovary syndrome Diseases 0.000 claims 2
- 201000011461 pre-eclampsia Diseases 0.000 claims 2
- 125000003373 pyrazinyl group Chemical group 0.000 claims 2
- 125000002098 pyridazinyl group Chemical group 0.000 claims 2
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 2
- 239000002464 receptor antagonist Substances 0.000 claims 2
- 229940044551 receptor antagonist Drugs 0.000 claims 2
- 231100000241 scar Toxicity 0.000 claims 2
- 230000037387 scars Effects 0.000 claims 2
- 231100000872 sexual dysfunction Toxicity 0.000 claims 2
- 125000006274 (C1-C3)alkoxy group Chemical group 0.000 claims 1
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 claims 1
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 claims 1
- GOKSXAJRWZYOPL-UHFFFAOYSA-N 1-(2-ethoxyethyl)-5-[ethyl(methyl)amino]-7-(4-fluoro-3-methylanilino)pyrazolo[4,3-d]pyrimidine-3-carboxylic acid Chemical compound C=12N(CCOCC)N=C(C(O)=O)C2=NC(N(C)CC)=NC=1NC1=CC=C(F)C(C)=C1 GOKSXAJRWZYOPL-UHFFFAOYSA-N 0.000 claims 1
- ULKQZAYKKRMQHT-UHFFFAOYSA-N 1-(2-ethoxyethyl)-5-[ethyl(methyl)amino]-7-[(2-methoxypyrimidin-4-yl)amino]pyrazolo[4,3-d]pyrimidine-3-carboxylic acid Chemical compound C=12N(CCOCC)N=C(C(O)=O)C2=NC(N(C)CC)=NC=1NC1=CC=NC(OC)=N1 ULKQZAYKKRMQHT-UHFFFAOYSA-N 0.000 claims 1
- VHDKFSITIVUYGS-UHFFFAOYSA-N 1-(2-ethoxyethyl)-7-[(4-methylpyridin-2-yl)amino]-5-(propan-2-ylamino)pyrazolo[4,3-d]pyrimidine-3-carboxylic acid Chemical compound C=12N(CCOCC)N=C(C(O)=O)C2=NC(NC(C)C)=NC=1NC1=CC(C)=CC=N1 VHDKFSITIVUYGS-UHFFFAOYSA-N 0.000 claims 1
- PHBHZBQVOZBEPW-UHFFFAOYSA-N 1-[2-(2,2-difluoroethoxy)ethyl]-5-[ethyl(methyl)amino]-7-[(4-methylpyridin-2-yl)amino]-n-methylsulfonylpyrazolo[4,3-d]pyrimidine-3-carboxamide Chemical compound C=12N(CCOCC(F)F)N=C(C(=O)NS(C)(=O)=O)C2=NC(N(C)CC)=NC=1NC1=CC(C)=CC=N1 PHBHZBQVOZBEPW-UHFFFAOYSA-N 0.000 claims 1
- UMJCJYXTGHKSEF-UHFFFAOYSA-N 1-[2-(2,2-difluoroethoxy)ethyl]-5-[methyl(propan-2-yl)amino]-7-[(4-methylpyridin-2-yl)amino]-n-methylsulfonylpyrazolo[4,3-d]pyrimidine-3-carboxamide Chemical compound C=12N(CCOCC(F)F)N=C(C(=O)NS(C)(=O)=O)C2=NC(N(C)C(C)C)=NC=1NC1=CC(C)=CC=N1 UMJCJYXTGHKSEF-UHFFFAOYSA-N 0.000 claims 1
- RUOASMKTCSCEFG-UHFFFAOYSA-N 1-[2-(3-fluoropropoxy)ethyl]-5-[methyl(propan-2-yl)amino]-7-[(4-methylpyridin-2-yl)amino]-n-methylsulfonylpyrazolo[4,3-d]pyrimidine-3-carboxamide Chemical compound C=12N(CCOCCCF)N=C(C(=O)NS(C)(=O)=O)C2=NC(N(C)C(C)C)=NC=1NC1=CC(C)=CC=N1 RUOASMKTCSCEFG-UHFFFAOYSA-N 0.000 claims 1
- QAPMQHSUOJHXEP-UHFFFAOYSA-N 1-[2-(cyclopropylmethoxy)ethyl]-5-[ethyl(methyl)amino]-7-[(4-methylpyridin-2-yl)amino]pyrazolo[4,3-d]pyrimidine-3-carboxylic acid Chemical class C=12N(CCOCC3CC3)N=C(C(O)=O)C2=NC(N(C)CC)=NC=1NC1=CC(C)=CC=N1 QAPMQHSUOJHXEP-UHFFFAOYSA-N 0.000 claims 1
- NVORJBTVWKLQKI-UHFFFAOYSA-N 1-[2-(cyclopropylmethoxy)ethyl]-5-[methyl(propan-2-yl)amino]-7-[(4-methylpyridin-2-yl)amino]pyrazolo[4,3-d]pyrimidine-3-carboxylic acid Chemical class C=12N(CCOCC3CC3)N=C(C(O)=O)C2=NC(N(C)C(C)C)=NC=1NC1=CC(C)=CC=N1 NVORJBTVWKLQKI-UHFFFAOYSA-N 0.000 claims 1
- 125000004206 2,2,2-trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 claims 1
- YGVZDIKWVXYLDL-UHFFFAOYSA-N 2-(dimethylamino)ethyl 5-(dimethylamino)-1-(2-ethoxyethyl)-7-[(4-methylpyridin-2-yl)amino]pyrazolo[4,3-d]pyrimidine-3-carboxylate Chemical compound C=12N(CCOCC)N=C(C(=O)OCCN(C)C)C2=NC(N(C)C)=NC=1NC1=CC(C)=CC=N1 YGVZDIKWVXYLDL-UHFFFAOYSA-N 0.000 claims 1
- FQAWADJQDGOZNN-UHFFFAOYSA-N 3-[1-(2-ethoxyethyl)-5-[methyl(propan-2-yl)amino]-7-[(4-methylpyridin-2-yl)amino]pyrazolo[4,3-d]pyrimidin-3-yl]-2h-1,2,4-oxadiazol-5-one Chemical compound C12=NC(N(C)C(C)C)=NC(NC=3N=CC=C(C)C=3)=C2N(CCOCC)N=C1C1=NC(=O)ON1 FQAWADJQDGOZNN-UHFFFAOYSA-N 0.000 claims 1
- XUIQMJKVVCTMKZ-UHFFFAOYSA-N 5-(diethylamino)-1-[2-(2,2-difluoroethoxy)ethyl]-7-[(4-methylpyridin-2-yl)amino]-n-methylsulfonylpyrazolo[4,3-d]pyrimidine-3-carboxamide Chemical compound C=12N(CCOCC(F)F)N=C(C(=O)NS(C)(=O)=O)C2=NC(N(CC)CC)=NC=1NC1=CC(C)=CC=N1 XUIQMJKVVCTMKZ-UHFFFAOYSA-N 0.000 claims 1
- OODLQWGZZKCNMK-UHFFFAOYSA-N 5-(diethylamino)-1-[2-(3-fluoropropoxy)ethyl]-7-[(4-methylpyridin-2-yl)amino]-n-methylsulfonylpyrazolo[4,3-d]pyrimidine-3-carboxamide Chemical compound C=12N(CCOCCCF)N=C(C(=O)NS(C)(=O)=O)C2=NC(N(CC)CC)=NC=1NC1=CC(C)=CC=N1 OODLQWGZZKCNMK-UHFFFAOYSA-N 0.000 claims 1
- USPKUTPIUYJNPU-UHFFFAOYSA-N 5-[cyclobutyl(methyl)amino]-1-(2-ethoxyethyl)-7-[(4-methylpyridin-2-yl)amino]pyrazolo[4,3-d]pyrimidine-3-carboxylic acid Chemical compound C=12N(CCOCC)N=C(C(O)=O)C2=NC(N(C)C2CCC2)=NC=1NC1=CC(C)=CC=N1 USPKUTPIUYJNPU-UHFFFAOYSA-N 0.000 claims 1
- VPOVDEQHKDSSOA-UHFFFAOYSA-N 5-[ethyl(methyl)amino]-1-[2-(3-fluoropropoxy)ethyl]-7-[(4-methylpyridin-2-yl)amino]-n-methylsulfonylpyrazolo[4,3-d]pyrimidine-3-carboxamide Chemical compound C=12N(CCOCCCF)N=C(C(=O)NS(C)(=O)=O)C2=NC(N(C)CC)=NC=1NC1=CC(C)=CC=N1 VPOVDEQHKDSSOA-UHFFFAOYSA-N 0.000 claims 1
- SHXHBGYPPYAGQC-UHFFFAOYSA-N 5-[methyl(propan-2-yl)amino]-7-[(4-methylpyridin-2-yl)amino]-1-(2-propan-2-yloxyethyl)pyrazolo[4,3-d]pyrimidine-3-carboxylic acid Chemical compound C=12N(CCOC(C)C)N=C(C(O)=O)C2=NC(N(C)C(C)C)=NC=1NC1=CC(C)=CC=N1 SHXHBGYPPYAGQC-UHFFFAOYSA-N 0.000 claims 1
- KSSDSJGVUIINBC-UHFFFAOYSA-N 5-[methyl(propan-2-yl)amino]-7-[(4-methylpyridin-2-yl)amino]-1-(2-propoxyethyl)pyrazolo[4,3-d]pyrimidine-3-carboxylic acid Chemical class C=12N(CCOCCC)N=C(C(O)=O)C2=NC(N(C)C(C)C)=NC=1NC1=CC(C)=CC=N1 KSSDSJGVUIINBC-UHFFFAOYSA-N 0.000 claims 1
- SODJGBFMTJXCCS-UHFFFAOYSA-N 7-(3,4-dimethylanilino)-1-(2-ethoxyethyl)-5-[ethyl(methyl)amino]pyrazolo[4,3-d]pyrimidine-3-carboxylic acid Chemical compound C=12N(CCOCC)N=C(C(O)=O)C2=NC(N(C)CC)=NC=1NC1=CC=C(C)C(C)=C1 SODJGBFMTJXCCS-UHFFFAOYSA-N 0.000 claims 1
- WLBIWMGZPYVCHV-UHFFFAOYSA-N 7-[(4,6-dimethylpyridin-2-yl)amino]-1-(2-ethoxyethyl)-5-[methyl(propan-2-yl)amino]pyrazolo[4,3-d]pyrimidine-3-carboxylic acid Chemical class C=12N(CCOCC)N=C(C(O)=O)C2=NC(N(C)C(C)C)=NC=1NC1=CC(C)=CC(C)=N1 WLBIWMGZPYVCHV-UHFFFAOYSA-N 0.000 claims 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 claims 1
- 102000004274 CCR5 Receptors Human genes 0.000 claims 1
- 108010017088 CCR5 Receptors Proteins 0.000 claims 1
- 229940127291 Calcium channel antagonist Drugs 0.000 claims 1
- 101100189582 Dictyostelium discoideum pdeD gene Proteins 0.000 claims 1
- 102000003979 Mineralocorticoid Receptors Human genes 0.000 claims 1
- 108090000375 Mineralocorticoid Receptors Proteins 0.000 claims 1
- 101150098694 PDE5A gene Proteins 0.000 claims 1
- 206010036049 Polycystic ovaries Diseases 0.000 claims 1
- 102000007637 Soluble Guanylyl Cyclase Human genes 0.000 claims 1
- 108010007205 Soluble Guanylyl Cyclase Proteins 0.000 claims 1
- 229940100389 Sulfonylurea Drugs 0.000 claims 1
- 229960001138 acetylsalicylic acid Drugs 0.000 claims 1
- 239000013543 active substance Substances 0.000 claims 1
- 239000002160 alpha blocker Substances 0.000 claims 1
- MDFFNEOEWAXZRQ-UHFFFAOYSA-N aminyl Chemical group [NH2] MDFFNEOEWAXZRQ-UHFFFAOYSA-N 0.000 claims 1
- 239000002333 angiotensin II receptor antagonist Substances 0.000 claims 1
- 239000003529 anticholesteremic agent Substances 0.000 claims 1
- 229940127226 anticholesterol agent Drugs 0.000 claims 1
- 239000003472 antidiabetic agent Substances 0.000 claims 1
- 229940125708 antidiabetic agent Drugs 0.000 claims 1
- 239000002220 antihypertensive agent Substances 0.000 claims 1
- 229940030600 antihypertensive agent Drugs 0.000 claims 1
- 230000009286 beneficial effect Effects 0.000 claims 1
- 239000002876 beta blocker Substances 0.000 claims 1
- 229940097320 beta blocking agent Drugs 0.000 claims 1
- 102100029175 cGMP-specific 3',5'-cyclic phosphodiesterase Human genes 0.000 claims 1
- 239000000480 calcium channel blocker Substances 0.000 claims 1
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 claims 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 125000006222 dimethylaminomethyl group Chemical group [H]C([H])([H])N(C([H])([H])[H])C([H])([H])* 0.000 claims 1
- 239000002934 diuretic Substances 0.000 claims 1
- 229940030606 diuretics Drugs 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000002792 enkephalinase inhibitor Substances 0.000 claims 1
- 125000006232 ethoxy propyl group Chemical group [H]C([H])([H])C([H])([H])OC([H])([H])C([H])([H])C([H])([H])* 0.000 claims 1
- 125000005448 ethoxyethyl group Chemical group [H]C([H])([H])C([H])([H])OC([H])([H])C([H])([H])* 0.000 claims 1
- MWJCGMSTJUEASS-UHFFFAOYSA-N ethyl 1-(2-ethoxyethyl)-5-[ethyl(methyl)amino]-7-[(4-methylpyridin-2-yl)amino]pyrazolo[4,3-d]pyrimidine-3-carboxylate Chemical compound C=12N(CCOCC)N=C(C(=O)OCC)C2=NC(N(C)CC)=NC=1NC1=CC(C)=CC=N1 MWJCGMSTJUEASS-UHFFFAOYSA-N 0.000 claims 1
- 229910052731 fluorine Inorganic materials 0.000 claims 1
- 239000011737 fluorine Substances 0.000 claims 1
- 125000001153 fluoro group Chemical group F* 0.000 claims 1
- 125000002541 furyl group Chemical group 0.000 claims 1
- 239000003119 guanylate cyclase activator Substances 0.000 claims 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 1
- 150000002462 imidazolines Chemical class 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims 1
- 125000001786 isothiazolyl group Chemical group 0.000 claims 1
- 239000003446 ligand Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- KTEHUXPXWAOYEE-UHFFFAOYSA-N methyl 1-(2-ethoxyethyl)-5-[methyl(propan-2-yl)amino]-7-[(6-methylpyridin-2-yl)amino]pyrazolo[4,3-d]pyrimidine-3-carboxylate Chemical compound C=12N(CCOCC)N=C(C(=O)OC)C2=NC(N(C)C(C)C)=NC=1NC1=CC=CC(C)=N1 KTEHUXPXWAOYEE-UHFFFAOYSA-N 0.000 claims 1
- VWDCNBWFAGYJNA-GJZGRUSLSA-N methyl 5-[(1s,4s)-2,5-diazabicyclo[2.2.1]heptan-2-yl]-1-(2-ethoxyethyl)-7-[(4-methylpyridin-2-yl)amino]pyrazolo[4,3-d]pyrimidine-3-carboxylate Chemical compound C([C@]1(NC[C@]2([H])C1)[H])N2C(N=C1C(C(=O)OC)=NN(CCOCC)C1=1)=NC=1NC1=CC(C)=CC=N1 VWDCNBWFAGYJNA-GJZGRUSLSA-N 0.000 claims 1
- 125000006533 methyl amino methyl group Chemical group [H]N(C([H])([H])[H])C([H])([H])* 0.000 claims 1
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 claims 1
- 208000004296 neuralgia Diseases 0.000 claims 1
- 208000021722 neuropathic pain Diseases 0.000 claims 1
- UUEVFMOUBSLVJW-UHFFFAOYSA-N oxo-[[1-[2-[2-[2-[4-(oxoazaniumylmethylidene)pyridin-1-yl]ethoxy]ethoxy]ethyl]pyridin-4-ylidene]methyl]azanium;dibromide Chemical compound [Br-].[Br-].C1=CC(=C[NH+]=O)C=CN1CCOCCOCCN1C=CC(=C[NH+]=O)C=C1 UUEVFMOUBSLVJW-UHFFFAOYSA-N 0.000 claims 1
- 125000004430 oxygen atom Chemical group O* 0.000 claims 1
- 125000004193 piperazinyl group Chemical group 0.000 claims 1
- AYXYPKUFHZROOJ-ZETCQYMHSA-N pregabalin Chemical compound CC(C)C[C@H](CN)CC(O)=O AYXYPKUFHZROOJ-ZETCQYMHSA-N 0.000 claims 1
- 229960001233 pregabalin Drugs 0.000 claims 1
- 125000006225 propoxyethyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])OC([H])([H])C([H])([H])* 0.000 claims 1
- 208000002815 pulmonary hypertension Diseases 0.000 claims 1
- 125000006513 pyridinyl methyl group Chemical group 0.000 claims 1
- 125000000168 pyrrolyl group Chemical group 0.000 claims 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 claims 1
- 125000006223 tetrahydrofuranylmethyl group Chemical group 0.000 claims 1
- 125000006173 tetrahydropyranylmethyl group Chemical group 0.000 claims 1
- 125000000335 thiazolyl group Chemical group 0.000 claims 1
- 125000001544 thienyl group Chemical group 0.000 claims 1
- 125000005843 halogen group Chemical group 0.000 abstract 3
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/582—Recycling of unreacted starting or intermediate materials
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0327319.0A GB0327319D0 (en) | 2003-11-24 | 2003-11-24 | Novel pharmaceuticals |
PCT/IB2004/003747 WO2005049616A1 (en) | 2003-11-24 | 2004-11-12 | 5,7-DIAMINOPYRAZOLO [4,3-d] PYRIMIDINES WITH PDE-5 INHIBITING ACTIVITY |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20100651T1 true HRP20100651T1 (hr) | 2011-01-31 |
Family
ID=29764364
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HR20100651T HRP20100651T1 (hr) | 2003-11-24 | 2010-11-26 | 5,7-DIAMINOPIRAZOLO[4,3-d]PIRIMIDINI S AKTIVNOSCU INHIBITORA PDE-5 |
Country Status (44)
Families Citing this family (49)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101084212A (zh) | 2004-09-20 | 2007-12-05 | 泽农医药公司 | 杂环衍生物及其作为硬脂酰CoA去饱和酶介导剂的用途 |
CN101084207A (zh) | 2004-09-20 | 2007-12-05 | 泽农医药公司 | 杂环衍生物及其作为硬脂酰CoA去饱和酶抑制剂的用途 |
WO2006034440A2 (en) | 2004-09-20 | 2006-03-30 | Xenon Pharmaceuticals Inc. | Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors |
US7592343B2 (en) | 2004-09-20 | 2009-09-22 | Xenon Pharmaceuticals Inc. | Pyridazine-piperazine compounds and their use as stearoyl-CoA desaturase inhibitors |
EP2289510A1 (en) | 2004-09-20 | 2011-03-02 | Xenon Pharmaceuticals Inc. | Heterocyclic derivatives for the treatment of diseases mediated by stearoyl-coa desaturase enzymes |
EP2316458A1 (en) | 2004-09-20 | 2011-05-04 | Xenon Pharmaceuticals Inc. | Pyridazine derivatives for inhibiting human stearoyl-coa-desaturase |
MX2007003321A (es) | 2004-09-20 | 2007-06-05 | Xenon Pharmaceuticals Inc | Derivados heterociclicos y su uso como agentes terapeuticos. |
CA2585557C (en) * | 2004-10-28 | 2009-08-18 | Pharmacia & Upjohn Company Llc | Pyrazolo[4,3-d] pyrimidine derivatives useful as pde-5 inhibitors |
US8227475B2 (en) * | 2005-05-12 | 2012-07-24 | Pfizer Inc. | Anhydrous crystalline forms of N-[1-(2-ethoxyethyl)-5-(N-ethyl-N-methylamino)-7-(4-methylpyridin-2-yl-amino)-1H-pyrazolo[4,3-d]pyrimidine-3-carbonyl]methanesulfonamide |
CN101208089A (zh) | 2005-06-03 | 2008-06-25 | 泽农医药公司 | 氨基噻唑衍生物作为人硬酯酰-CoA去饱和酶抑制剂 |
NL1029244C2 (nl) * | 2005-06-10 | 2006-12-12 | Ronald Silfried Marlin | Middel ter vergroting van het mannelijk geslachtsorgaan. |
DE102005050377A1 (de) * | 2005-10-21 | 2007-04-26 | Bayer Healthcare Ag | Heterocyclische Verbindungen und ihre Verwendung |
NL2000291C2 (nl) | 2005-11-10 | 2009-02-17 | Pfizer Prod Inc | 1-(1-(2-ethoxyethyl)-3-ethyl-7-(4-methylpyridin-2-ylamino)-1H- pyrazool(4,3-d)pyrimidine-5-yl)piperidine-4-carbonzuur en zouten daarvan. |
WO2007070872A1 (en) | 2005-12-15 | 2007-06-21 | Rigel Pharmaceuticals, Inc. | Kinase inhibitors and their uses |
EP1820502A1 (en) * | 2006-02-10 | 2007-08-22 | Laboratorios Del Dr. Esteve, S.A. | Active substance combination comprising azolylcarbinol compounds |
WO2007113243A2 (en) * | 2006-03-31 | 2007-10-11 | Investigación Y Clínica Andrológicas S.L. | Use of pde 5 inhibitors for the treatment of overactive bladder |
WO2008132589A1 (en) * | 2007-05-01 | 2008-11-06 | Pfizer Limited | Combinations comprising pregabalin |
WO2009050554A2 (en) * | 2007-10-19 | 2009-04-23 | Pfizer Inc. | Treatment of central nervous system disorders |
DE102008063992A1 (de) * | 2008-12-19 | 2010-09-02 | Lerner, Zinoviy, Dipl.-Ing. | Neue aliphatisch substituierte Pyrazolopyridine und ihre Verwendung |
WO2012131539A1 (en) | 2011-03-31 | 2012-10-04 | Pfizer Inc. | Novel bicyclic pyridinones |
WO2012172449A1 (en) | 2011-06-13 | 2012-12-20 | Pfizer Inc. | Lactams as beta secretase inhibitors |
EP2751116B1 (en) | 2011-08-31 | 2016-10-12 | Pfizer Inc | Hexahydropyrano [3,4-d][1,3]thiazin-2-amine compounds |
JP6110937B2 (ja) | 2012-05-04 | 2017-04-05 | ファイザー・インク | APP、BACE1、およびBACE2の阻害剤としての複素環式置換ヘキサヒドロピラノ[3,4−d][1,3]チアジン−2−アミン化合物 |
JP2015529239A (ja) | 2012-09-20 | 2015-10-05 | ファイザー・インク | アルキル置換ヘキサヒドロピラノ[3,4−d][1,3]チアジン−2−アミン化合物 |
UA110688C2 (uk) | 2012-09-21 | 2016-01-25 | Пфайзер Інк. | Біциклічні піридинони |
EP2931731A1 (en) | 2012-12-11 | 2015-10-21 | Pfizer Inc. | Hexahydropyrano [3,4-d][1,3]thiazin-2-amine compounds as inhibitors of bace1 |
EP2935282A1 (en) | 2012-12-19 | 2015-10-28 | Pfizer Inc. | CARBOCYCLIC- AND HETEROCYCLIC-SUBSTITUTED HEXAHYDROPYRANO[3,4-d][1,3]THIAZIN-2-AMINE COMPOUNDS |
WO2014125394A1 (en) | 2013-02-13 | 2014-08-21 | Pfizer Inc. | HETEROARYL-SUBSTITUTED HEXAHYDROPYRANO [3,4-d][1,3] THIAZIN-2-AMINE COMPOUNDS |
US9233981B1 (en) | 2013-02-15 | 2016-01-12 | Pfizer Inc. | Substituted phenyl hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds |
AP2015008663A0 (en) | 2013-02-19 | 2015-08-31 | Pfizer | Azabenzimidazole compounds as inhibitors of PDE4 isozymes for the treatment of cns and other disorders |
ES2742078T3 (es) | 2013-10-04 | 2020-02-13 | Pfizer | Piridonas bicíclicas novedosas como moduladores de gamma-secretasa |
US20170037028A1 (en) * | 2013-12-20 | 2017-02-09 | Bayer Pharma Aktiengesellschaft | Glucose transport inhibitors |
KR101886945B1 (ko) | 2014-04-01 | 2018-08-08 | 화이자 인코포레이티드 | 감마-세크레타제 조절제로서의 크로멘 및 1,1a,2,7b-테트라히드로시클로프로파[c]크로멘 피리도피라진디온 |
DK3126354T3 (da) * | 2014-04-04 | 2020-03-09 | H Lundbeck As | Halogenerede quinazolin-thf-aminer som pde1-inhibitorer |
MD20160105A2 (ro) | 2014-04-10 | 2017-03-31 | Pfizer Inc. | 2-Amino-6-metil-4,4a,5,6-tetrahidropirano[3,4-d][1,3]tiazin-8a(8H)-il-1,3-tiazol-4-il amide |
JP6713982B2 (ja) | 2014-07-24 | 2020-06-24 | ファイザー・インク | ピラゾロピリミジン化合物 |
CU20170007A7 (es) | 2014-08-06 | 2017-06-05 | Pfizer | Compuestos de imidazopiridazina |
EA032081B1 (ru) * | 2014-12-08 | 2019-04-30 | Янссен Сайенсиз Айрлэнд Юси | ЗАМЕЩЕННЫЕ ПИПЕРИДИНОМ ПРОИЗВОДНЫЕ ПИРАЗОЛО[1,5-a]ПИРИМИДИНА С ИНГИБИРУЮЩЕЙ АКТИВНОСТЬЮ В ОТНОШЕНИИ РЕПЛИКАЦИИ РЕСПИРАТОРНО-СИНЦИТИАЛЬНОГО ВИРУСА (RSV) |
MX368391B (es) | 2015-02-03 | 2019-09-30 | Pfizer | Ciclopropabenzofuranil-piridopirazindionas novedosas. |
CN107787322B (zh) | 2015-06-17 | 2023-07-07 | 辉瑞大药厂 | 三环化合物以及它们作为磷酸二酯酶抑制剂的用途 |
WO2017051276A1 (en) | 2015-09-24 | 2017-03-30 | Pfizer Inc. | N-[2-(2-amino-6,6-disubstituted-4, 4a, 5, 6-tetrahydropyrano [3,4-d][1,3] thiazin-8a (8h)-yl) -1, 3-thiazol-4-yl] amides |
EP3353182A1 (en) | 2015-09-24 | 2018-08-01 | Pfizer Inc | Tetrahydropyrano[3,4-d][1,3]oxazin derivatives and their use as bace inhibitors |
JP2018534251A (ja) | 2015-09-24 | 2018-11-22 | ファイザー・インク | Bace阻害剤として有用なn−[2−(3−アミノ−2,5−ジメチル−1,1−ジオキシド−5,6−ジヒドロ−2h−1,2,4−チアジアジン−5−イル)−1,3−チアゾール−4−イル]アミド |
EP3419979B1 (en) | 2016-02-23 | 2020-01-29 | Pfizer Inc | 6,7-dihydro-5h-pyrazolo[5,1-b][1,3]oxazine-2-carboxamide compounds |
EP3872078A1 (en) | 2016-07-01 | 2021-09-01 | Pfizer Inc. | 5,7-dihydro-pyrrolo-pyridine derivatives for use in the treament of depression, anxiety or panic disorders |
JP7263266B2 (ja) | 2017-06-22 | 2023-04-24 | ファイザー・インク | ジヒドロ-ピロロ-ピリジン誘導体 |
WO2019183636A1 (en) | 2018-03-23 | 2019-09-26 | Pfizer Inc. | Piperazine azaspiro derivaves |
BR112020024700A2 (pt) | 2018-06-04 | 2021-03-02 | Exscientia Ltd | compostos de pirazolopirimidina como antagonistas receptores de adenosina |
US10800767B2 (en) * | 2018-08-24 | 2020-10-13 | Terns, Inc. | Thyroid hormone receptor beta agonist compounds |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW444018B (en) * | 1992-12-17 | 2001-07-01 | Pfizer | Pyrazolopyrimidines |
GB9823102D0 (en) * | 1998-10-23 | 1998-12-16 | Pfizer Ltd | Pharmaceutically active compounds |
BR9915532A (pt) * | 1998-10-23 | 2001-08-14 | Pfizer | Inibidores de cgmp pde5 de pirazolopirimidinona para tratamento da disfunção sexual |
DE10031236A1 (de) * | 2000-06-27 | 2002-01-10 | Qiagen Gmbh | Verwendung von Carbonsäuren und anderen Additiven in Kombination mit kationischen Verbindungen zur Stabilisierung von Nukleinsäuren in biologischen Materialien |
DE10031584A1 (de) * | 2000-06-29 | 2002-01-10 | Merck Patent Gmbh | 5-Aminoalkyl-pyrazolo[4,3-d]pyrimidine |
DK1348707T3 (da) * | 2002-03-28 | 2010-12-13 | Ustav Ex Botan Av Cr V V I Inst Of Ex Botany Academy Of Sciences Of The Czech Republic Pro | Pyrazolo[4,3-d]pyrimidiner, fremgangsmåder til deres fremstilling samt deres terapeutiske anvendelse |
WO2004096810A1 (en) | 2003-04-29 | 2004-11-11 | Pfizer Limited | 5,7-diaminopyrazolo`4,3-d!pyrimidines useful in the treatment of hypertension |
-
2003
- 2003-11-24 GB GBGB0327319.0A patent/GB0327319D0/en not_active Ceased
-
2004
- 2004-11-12 CA CA002546987A patent/CA2546987C/en not_active Expired - Fee Related
- 2004-11-12 EA EA200600677A patent/EA011772B1/ru not_active IP Right Cessation
- 2004-11-12 GE GEAP20049412A patent/GEP20084528B/en unknown
- 2004-11-12 CN CN2008100859397A patent/CN101362764B/zh not_active Expired - Fee Related
- 2004-11-12 BR BRPI0416869-0A patent/BRPI0416869A/pt not_active Application Discontinuation
- 2004-11-12 KR KR1020087009034A patent/KR100893999B1/ko not_active IP Right Cessation
- 2004-11-12 MX MXPA06005914A patent/MXPA06005914A/es active IP Right Grant
- 2004-11-12 PL PL04798876T patent/PL1689751T3/pl unknown
- 2004-11-12 AT AT04798876T patent/ATE485297T1/de active
- 2004-11-12 ES ES04798876T patent/ES2351622T3/es active Active
- 2004-11-12 KR KR1020067010152A patent/KR100848216B1/ko not_active IP Right Cessation
- 2004-11-12 JP JP2006540647A patent/JP4056015B2/ja not_active Expired - Fee Related
- 2004-11-12 OA OA1200600166A patent/OA13289A/en unknown
- 2004-11-12 DK DK04798876.1T patent/DK1689751T3/da active
- 2004-11-12 PT PT04798876T patent/PT1689751E/pt unknown
- 2004-11-12 SI SI200431562T patent/SI1689751T1/sl unknown
- 2004-11-12 CN CN200910151866A patent/CN101647802A/zh active Pending
- 2004-11-12 EP EP04798876A patent/EP1689751B1/en active Active
- 2004-11-12 AP AP2006003591A patent/AP2227A/xx active
- 2004-11-12 CN CN200810085940XA patent/CN101362765B/zh not_active Expired - Fee Related
- 2004-11-12 ME MEP-2010-203A patent/ME01216B/me unknown
- 2004-11-12 SG SG200704860-6A patent/SG133614A1/en unknown
- 2004-11-12 NZ NZ548097A patent/NZ548097A/en not_active IP Right Cessation
- 2004-11-12 CN CN2004800345707A patent/CN1882591B/zh not_active Expired - Fee Related
- 2004-11-12 AU AU2004290643A patent/AU2004290643B2/en not_active Ceased
- 2004-11-12 DE DE602004029705T patent/DE602004029705D1/de active Active
- 2004-11-12 WO PCT/IB2004/003747 patent/WO2005049616A1/en active Application Filing
- 2004-11-12 RS RSP-2010/0534A patent/RS51556B/en unknown
- 2004-11-22 MY MYPI20044834A patent/MY140872A/en unknown
- 2004-11-22 UY UY28625A patent/UY28625A1/es active IP Right Grant
- 2004-11-22 PE PE2004001138A patent/PE20051061A1/es not_active Application Discontinuation
- 2004-11-23 TW TW093136019A patent/TWI265031B/zh not_active IP Right Cessation
- 2004-11-23 AR ARP040104331A patent/AR046711A1/es not_active Application Discontinuation
- 2004-11-23 NL NL1027568A patent/NL1027568C2/nl not_active IP Right Cessation
- 2004-11-23 PA PA20048617701A patent/PA8617701A1/es unknown
- 2004-12-11 UA UAA200605669A patent/UA81994C2/uk unknown
-
2006
- 2006-04-10 ZA ZA200602899A patent/ZA200602899B/en unknown
- 2006-04-10 IS IS8406A patent/IS8406A/is unknown
- 2006-05-04 IL IL175433A patent/IL175433A/en not_active IP Right Cessation
- 2006-05-23 CR CR8416A patent/CR8416A/es unknown
- 2006-05-23 EC EC2006006580A patent/ECSP066580A/es unknown
- 2006-05-24 MA MA29050A patent/MA28172A1/fr unknown
- 2006-05-24 TN TNP2006000154A patent/TNSN06154A1/fr unknown
- 2006-06-23 NO NO20062950A patent/NO336526B1/no not_active IP Right Cessation
-
2007
- 2007-05-22 HK HK07105414.0A patent/HK1099286A1/xx not_active IP Right Cessation
-
2009
- 2009-08-03 HK HK09107080.7A patent/HK1128917A1/xx not_active IP Right Cessation
-
2010
- 2010-11-24 CY CY20101101062T patent/CY1110933T1/el unknown
- 2010-11-26 HR HR20100651T patent/HRP20100651T1/hr unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20100651T1 (hr) | 5,7-DIAMINOPIRAZOLO[4,3-d]PIRIMIDINI S AKTIVNOSCU INHIBITORA PDE-5 | |
AU2017382029B2 (en) | Bicyclic dihydropyrimidine-carboxamide derivatives as Rho-kinase inhibitors | |
AU2011257336B2 (en) | The use of sGC stimulators, sGC activators, alone and combinations with PDE5 inhibitors for the treatment of systemic sclerosis (SSc). | |
AU2011258436B2 (en) | Soluble guanylate cyclase activators | |
AU2018212593B2 (en) | Tyrosine amide derivatives as Rho- kinase inhibitors | |
JP6054967B2 (ja) | 置換アネレート化ピリミジンおよびその使用 | |
KR101345956B1 (ko) | Vegf-r2의 피리딜옥시인돌 억제제 및 질환의 치료를 위한 그의 용도 | |
ES2652514T3 (es) | Compuestos heteroaromáticos como ligandos de dopamina D1 | |
CA2743864A1 (en) | Soluble guanylate cyclase activators | |
ES2807785T3 (es) | Compuestos de heteroarilamina bicíclicos como inhibidores de pi3k | |
AU2008318491A1 (en) | Cytokine inhibitors | |
JP2018529739A (ja) | セピアプテリン還元酵素としてのヘテロアリール誘導体 | |
CA2702315A1 (en) | Combination 059 | |
JP2006502119A (ja) | 新規2,5−二置換ピリミジン誘導体 | |
JP2005506304A (ja) | ホスホジエステラーゼ(pde)7の融合ヘテロ環阻害剤 | |
CA2958671C (en) | Imidazopyridazine compounds and their use | |
SG192756A1 (en) | 6 - cyclobutyl - 1, 5 - dihydro - pyrazolo [3, 4-d] pyrimidin- 4 - one derivatives their use as pde9a inhibitors | |
BR112016024455B1 (pt) | Composto heterocíclico bicíclico ou tricíclico | |
ES2208063A1 (es) | Nuevos derivados de la 4-(pirrolopirimidin-6-il)bencenosulfonamida. | |
WO2023150681A1 (en) | Inhibitors of raf kinases | |
AU2022249724A1 (en) | Pharmaceutical compound |